<![CDATA[Relacorilant Combo Receives Positive CHMP Opinion in Ovarian Cancer]]>

Regulatorypositiverelacorilantnab-paclitaxelPositive

AI Analysis

Summary

The European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer based on ROSELLA trial data.

Clinical Trial Data

Outcome Details

CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer

Importance:8/10

Sentiment:

0.85

ovarian cancerEMACHMPcombination therapyregulatory approval

Related Companies

$CORT

Read the original article

Published by Cancer Network on September 18, 2026 2:30 PM

Read Original